FN2 Earnings Intelligence
Waters Corporation earnings overview
Latest Waters Corporation (WAT) earnings intelligence, including the newest scorecard, market reaction, and transcript analysis.
Waters Corporation
Waters' Q2 results support a constructive operating picture: organic growth exceeded guidance, the acquired BD businesses accelerated, and cost actions supported margin expansion. The thesis depends on sustained pricing, integration execution, and demand for instrument replacements.
Waters Corporation
Waters Corporation delivered a decisive first-quarter beat, with revenue of $1.267 billion (13% organic growth) and adjusted EPS of $2.70 (+20% YoY), both above the high end of guidance and consensus. The stock surged over 13% on the report. Management raised full-year organic revenue guidance to 6.5-8% from ~5.3% and EPS to $14.40-$14.60 from $14.30-$14.50, reflecting early traction on BD integration synergies and broad-based instrument demand. The acquisition of BD's Biosciences and Diagnostic Solutions business is already generating $35 million in revenue synergies through cross-selling and pricing actions. Key regulatory milestones -- FDA clearance for an HPV self-collection kit and CE marking for the BACTEC FXI system ahead of schedule -- position Waters for continued product-driven growth. The prior quarter's tone of confident integration preparation has shifted to confident…
Waters Corporation
The quarter supports a constructive operating case based on resilient demand and recurring-revenue initiatives, but the next phase depends on executing the BD integration and managing the Empower transition without undermining instrument sales.
Waters Corporation
The current analysis supports a constructive but conditional view: resilient instrument and pharma-related demand, testing activity, product launches, and the planned BD combination support continued growth, while integration, product adoption, tariffs, funding, and regulatory uncertainty temper the case.
Waters Corporation
The supplied analysis supports a constructive operating thesis for Waters: resilient LCMS and recurring chemistry demand, raised guidance, and potential BD synergies outweigh near-term pressure from TA weakness, tariffs, funding, and integration risk. The relative event-session decline shows that strong fundamentals did not translate into an immediately positive market reaction.
Waters Corporation
The supplied analysis is supportive but conditional for the one-year growth hypothesis: stronger instrument demand, testing-related drivers, new products, and raised guidance support the case, while tariffs, pricing durability, and uneven end markets argue for continued verification.
Waters Corporation
The supplied analysis supports a constructive but conditional view: resilient recurring revenue, new-product adoption and replacement demand provide growth support, while the outlook remains dependent on China and broader research-market recovery.
Waters Corporation
The current analysis supports a cautiously constructive operating thesis: Waters is showing early instrument recovery, recurring-revenue growth, and product-led demand, while higher EPS guidance indicates margin support. The evidence is not unambiguously positive because full-year organic sales guidance remains negative and execution depends on replacement-cycle recovery and China demand.
Get the WAT recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.